Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Burlington Stores Inc (BURL) Price & Performance

AstraZeneca plcTrade
Burlington Stores IncTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Burlington Stores Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Burlington Stores Inc trades at $354.86 (market cap $22.59B). The key difference: AstraZeneca plc is far larger — about 11× Burlington Stores Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.

AZNBURL
Market Cap
$248.14B$22.59B
Sector
HealthConsumer Cyclical
52-Week High
$209.48$372.19
52-Week Low
$147.06$242.43
Enterprise Value
$275.41B$27.71B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Burlington Stores Inc

Burlington Stores (BURL) trades at $353.63, down 4.81% in the last session but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical setup with key support at $346 and resistance at $365, while fundamentals reveal impressive profitability with 39.14% ROE and expanding margins. Recent news highlights the company's successful smaller-store strategy and upward revised 2026 outlook.

BURL presents a compelling growth opportunity with 94% analyst buy ratings and a $367 consensus target offering 3.8% upside. However, elevated valuation multiples (P/E 36.92) and competitive retail pressures warrant caution. The company's debt-to-asset ratio rising to 20.99% in 2026 and recent insider selling of $619,200 worth of shares represent notable risk factors for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL